<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Pharmaceutics</journal-id><journal-id journal-id-type="iso-abbrev">Pharmaceutics</journal-id><journal-id journal-id-type="pmc-domain-id">2103</journal-id><journal-id journal-id-type="pmc-domain">pharmamdpi</journal-id><journal-id journal-id-type="publisher-id">pharmaceutics</journal-id><journal-title-group><journal-title>Pharmaceutics</journal-title></journal-title-group><issn pub-type="epub">1999-4923</issn><publisher><publisher-name>Multidisciplinary Digital Publishing Institute  (MDPI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC8709176</article-id><article-id pub-id-type="pmcid-ver">PMC8709176.1</article-id><article-id pub-id-type="pmcaid">8709176</article-id><article-id pub-id-type="pmcaiid">8709176</article-id><article-id pub-id-type="pmid">34959451</article-id><article-id pub-id-type="doi">10.3390/pharmaceutics13122170</article-id><article-id pub-id-type="publisher-id">pharmaceutics-13-02170</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Parametric and Nonparametric Population Pharmacokinetic Models to Assess Probability of Target Attainment of Imipenem Concentrations in Critically Ill Patients</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>de Velde</surname><given-names initials="F">Femke</given-names></name><xref rid="af1-pharmaceutics-13-02170" ref-type="aff">1</xref><xref rid="c1-pharmaceutics-13-02170" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>de Winter</surname><given-names initials="BCM">Brenda C. M.</given-names></name><xref rid="af2-pharmaceutics-13-02170" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Neely</surname><given-names initials="MN">Michael N.</given-names></name><xref rid="af3-pharmaceutics-13-02170" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Strojil</surname><given-names initials="J">Jan</given-names></name><xref rid="af4-pharmaceutics-13-02170" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-3512-9202</contrib-id><name name-style="western"><surname>Yamada</surname><given-names initials="WM">Walter M.</given-names></name><xref rid="af3-pharmaceutics-13-02170" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Harbarth</surname><given-names initials="S">Stephan</given-names></name><xref rid="af5-pharmaceutics-13-02170" ref-type="aff">5</xref><xref rid="af6-pharmaceutics-13-02170" ref-type="aff">6</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Huttner</surname><given-names initials="A">Angela</given-names></name><xref rid="af5-pharmaceutics-13-02170" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>van Gelder</surname><given-names initials="T">Teun</given-names></name><xref rid="af2-pharmaceutics-13-02170" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Koch</surname><given-names initials="BCP">Birgit C. P.</given-names></name><xref rid="af2-pharmaceutics-13-02170" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-5042-6251</contrib-id><name name-style="western"><surname>Muller</surname><given-names initials="AE">Anouk E.</given-names></name><xref rid="af1-pharmaceutics-13-02170" ref-type="aff">1</xref><xref rid="af7-pharmaceutics-13-02170" ref-type="aff">7</xref></contrib><contrib contrib-type="author"><collab>on behalf of the COMBACTE-NET Consortium</collab><xref rid="fn1-pharmaceutics-13-02170" ref-type="author-notes">&#8224;</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>P&#233;rez-Blanco</surname><given-names initials="JS">Jon&#225;s Samuel</given-names></name><role>Academic Editor</role></contrib><contrib contrib-type="editor"><name name-style="western"><surname>Lanao</surname><given-names initials="JM">Jos&#233; Mart&#237;nez</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-pharmaceutics-13-02170"><label>1</label>Department of Medical Microbiology and Infectious Diseases, Erasmus University Medical Center, 3000 CA Rotterdam, The Netherlands; <email>anoukemuller@gmail.com</email></aff><aff id="af2-pharmaceutics-13-02170"><label>2</label>Department of Hospital Pharmacy, Erasmus University Medical Center, 3000 CA Rotterdam, The Netherlands; <email>b.dewinter@erasmusmc.nl</email> (B.C.M.d.W.); <email>t.vangelder@erasmusmc.nl</email> (T.v.G.); <email>B.koch@erasmusmc.nl</email> (B.C.P.K.)</aff><aff id="af3-pharmaceutics-13-02170"><label>3</label>Laboratory of Applied Pharmacokinetics, Keck School of Medicine, University of Southern California, Los Angeles, CA 90027, USA; <email>mneely@chla.usc.edu</email> (M.N.N.); <email>wyamada@chla.usc.edu</email> (W.M.Y.)</aff><aff id="af4-pharmaceutics-13-02170"><label>4</label>Department of Pharmacology, Palacky University, CZ-779 00 Olomouc, Czech Republic; <email>jan.strojil@upol.cz</email></aff><aff id="af5-pharmaceutics-13-02170"><label>5</label>Division of Infectious Diseases, Faculty of Medicine, Geneva University Hospitals, 1205 Geneva, Switzerland; <email>stephan.harbarth@hcuge.ch</email> (S.H.); <email>Angela.Huttner@hcuge.ch</email> (A.H.)</aff><aff id="af6-pharmaceutics-13-02170"><label>6</label>Infection Control Program, Faculty of Medicine, Geneva University Hospitals, 1205 Geneva, Switzerland</aff><aff id="af7-pharmaceutics-13-02170"><label>7</label>Department of Medical Microbiology, Haaglanden Medical Centre, 2501 CK The Hague, The Netherlands</aff><author-notes><corresp id="c1-pharmaceutics-13-02170"><label>*</label>Correspondence: <email>femkedevelde@gmail.com</email></corresp><fn id="fn1-pharmaceutics-13-02170"><label>&#8224;</label><p>Membership of the COMBACTE-NET Consortium is provided in the Acknowledgment.</p></fn></author-notes><pub-date pub-type="epub"><day>16</day><month>12</month><year>2021</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2021</year></pub-date><volume>13</volume><issue>12</issue><issue-id pub-id-type="pmc-issue-id">396520</issue-id><elocation-id>2170</elocation-id><history><date date-type="received"><day>09</day><month>11</month><year>2021</year></date><date date-type="accepted"><day>10</day><month>12</month><year>2021</year></date></history><pub-history><event event-type="pmc-release"><date><day>16</day><month>12</month><year>2021</year></date></event><event event-type="pmc-live"><date><day>25</day><month>12</month><year>2021</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2021-12-30 05:16:41.447"><day>30</day><month>12</month><year>2021</year></date></event></pub-history><permissions><copyright-statement>&#169; 2021 by the authors.</copyright-statement><copyright-year>2021</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="pharmaceutics-13-02170.pdf"/><abstract><p>Population pharmacokinetic modeling and simulation (M&amp;S) are used to improve antibiotic dosing. Little is known about the differences in parametric and nonparametric M&amp;S. Our objectives were to compare (1) the external validation of parametric and nonparametric models of imipenem in critically ill patients and (2) the probability of target attainment (PTA) calculations using simulations of both models. The M&amp;S software used was NONMEM 7.2 (parametric) and Pmetrics 1.5.2 (nonparametric). The external predictive performance of both models was adequate for eGFRs &#8805; 78 mL/min but insufficient for lower eGFRs, indicating that the models (developed using a population with eGFR &#8805; 60 mL/min) could not be extrapolated to lower eGFRs. Simulations were performed for three dosing regimens and three eGFRs (90, 120, 150 mL/min). Fifty percent of the PTA results were similar for both models, while for the other 50% the nonparametric model resulted in lower MICs. This was explained by a higher estimated between-subject variability of the nonparametric model. Simulations indicated that 1000 mg q6h is suitable to reach MICs of 2 mg/L for eGFRs of 90&#8211;120 mL/min. For MICs of 4 mg/L and for higher eGFRs, dosing recommendations are missing due to largely different PTA values per model. The consequences of the different modeling approaches in clinical practice should be further investigated.</p></abstract><kwd-group><kwd>imipenem</kwd><kwd>population pharmacokinetic modeling</kwd><kwd>parametric</kwd><kwd>nonparametric</kwd><kwd>simulations</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1-pharmaceutics-13-02170"><title>1. Introduction</title><p>Population pharmacokinetic (popPK) modeling and simulation is used to improve antibiotic dosing and clinical outcomes of infections. Antimicrobial efficacy is determined by the susceptibility of the drug in vitro (usually expressed as the minimal inhibitory concentration, MIC) and the exposure to the drug in vivo, which relies on the pharmacokinetics and the dose [<xref rid="B1-pharmaceutics-13-02170" ref-type="bibr">1</xref>]. PopPK models describe the variability of exposure to a drug, and are therefore used to support dosing optimization. This optimization can take place in different ways: individualization of dosing via therapeutic drug monitoring (TDM) software, improving dosing regimens from the package insert (especially for specific subpopulations), and setting clinical breakpoints on a population level [<xref rid="B2-pharmaceutics-13-02170" ref-type="bibr">2</xref>]. Clinical breakpoints are MICs that categorize microorganisms as susceptible or resistant to specific antibiotics [<xref rid="B3-pharmaceutics-13-02170" ref-type="bibr">3</xref>]. </p><p>Several popPK modeling methods are available. Statistically, they are classified as either parametric or nonparametric methods [<xref rid="B2-pharmaceutics-13-02170" ref-type="bibr">2</xref>]. Parametric methods assume that the population parameter distribution is known, with unknown population parameter estimates [<xref rid="B4-pharmaceutics-13-02170" ref-type="bibr">4</xref>]. Nonparametric methods make no assumption about the shapes of the underlying parameter distributions, by which, theoretically, subpopulations are more easily detected [<xref rid="B5-pharmaceutics-13-02170" ref-type="bibr">5</xref>]. Many parametric and nonparametric popPK models are published in the literature, often accompanied by simulations of the model which lead to dosing recommendations [<xref rid="B2-pharmaceutics-13-02170" ref-type="bibr">2</xref>]. Little is known about the differences in modeling and simulation results between parametric and nonparametric methods, which may influence dosing recommendations. </p><p>Previously, we described the development and results of parametric and nonparametric popPK models of imipenem in critically ill patients [<xref rid="B6-pharmaceutics-13-02170" ref-type="bibr">6</xref>]. Both models described imipenem popPK well, and the population parameter estimates were similar. The same covariate was included: the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) eGFR (estimated Glomerular Filtration Range) equation [<xref rid="B7-pharmaceutics-13-02170" ref-type="bibr">7</xref>], which was unadjusted for body surface area, on elimination rate K<sub>e</sub>. The estimated between-subject variability (BSV) was higher in the nonparametric model. External validation and simulations of both models were not yet performed.</p><p>Like other beta-lactams, the antibacterial effect of imipenem is determined by the percent of time of the dosing interval during which the free concentration remains above the MIC (<italic toggle="yes">f</italic>T <sub>&gt; MIC</sub>) [<xref rid="B8-pharmaceutics-13-02170" ref-type="bibr">8</xref>]. Reported targets for beta-lactam antibiotics range from 20 to 100% <italic toggle="yes">f</italic>T <sub>&gt; MIC</sub> to 100% <italic toggle="yes">f</italic>T <sub>&gt; 5xMIC</sub> [<xref rid="B9-pharmaceutics-13-02170" ref-type="bibr">9</xref>,<xref rid="B10-pharmaceutics-13-02170" ref-type="bibr">10</xref>,<xref rid="B11-pharmaceutics-13-02170" ref-type="bibr">11</xref>,<xref rid="B12-pharmaceutics-13-02170" ref-type="bibr">12</xref>,<xref rid="B13-pharmaceutics-13-02170" ref-type="bibr">13</xref>]. Smaller preclinical and clinical studies suggest that the required targets seem to be the highest in cephalosporines, followed by penicillins, and then carbapenems [<xref rid="B11-pharmaceutics-13-02170" ref-type="bibr">11</xref>,<xref rid="B14-pharmaceutics-13-02170" ref-type="bibr">14</xref>]. Other M&amp;S studies of imipenem in critically ill patients used targets of 20&#8211;100% <italic toggle="yes">f</italic>T <sub>&gt; MIC</sub> [<xref rid="B15-pharmaceutics-13-02170" ref-type="bibr">15</xref>,<xref rid="B16-pharmaceutics-13-02170" ref-type="bibr">16</xref>,<xref rid="B17-pharmaceutics-13-02170" ref-type="bibr">17</xref>]. The DALI study showed a significant association of positive clinical outcome (defined as no switch of addition of antibiotics needed) with 50% <italic toggle="yes">f</italic>T <sub>&gt; MIC</sub> (OR 1.02) and 100% <italic toggle="yes">f</italic>T <sub>&gt; MIC</sub> (OR 1.56) for eight beta-lactams in 361 critically ill patients [<xref rid="B18-pharmaceutics-13-02170" ref-type="bibr">18</xref>]. However, this study did not distinguish between the three classes of beta-lactams. Due to the lack of consensus about the target, we chose to use two targets in this paper (50% <italic toggle="yes">f</italic>T <sub>&gt; MIC</sub> and 100% <italic toggle="yes">f</italic>T <sub>&gt; MIC</sub>). A Swiss study in hospitalized patients treated with standard imipenem dosing regimens from the package insert found a trend towards increased clinical failure in case of trough levels &lt; 2 mg/L (11% vs. 19%), indicating that the dosing could be optimized. Unfortunately, this study was underpowered to detect a significant difference [<xref rid="B19-pharmaceutics-13-02170" ref-type="bibr">19</xref>].</p><p>The first objective of the current study was to determine which of the two previously described imipenem models [<xref rid="B6-pharmaceutics-13-02170" ref-type="bibr">6</xref>] delivers the best Bayesian posterior estimates to predict the imipenem concentrations in an external independent database. The second objective was to determine the probability of target attainment (PTA) for several doses and estimated glomerular filtration rate (eGFR) values using simulations of both models.</p></sec><sec id="sec2-pharmaceutics-13-02170"><title>2. Materials and Methods</title><sec id="sec2dot1-pharmaceutics-13-02170"><title>2.1. Population PK Models</title><p>Two previously published parametric (using NONMEM 7.2) and nonparametric (using Pmetrics 1.5.2) population PK models of imipenem in critically ill patients were used for the analyses in this paper. The development and results of both models are described in detail elsewhere [<xref rid="B6-pharmaceutics-13-02170" ref-type="bibr">6</xref>]. Both models included two distribution compartments and the absolute (unadjusted for body surface area) CKD-EPI eGFR [<xref rid="B7-pharmaceutics-13-02170" ref-type="bibr">7</xref>] as a covariate on the elimination rate constant (K<sub>e</sub>). The parameter estimates in both models were comparable, except from the estimated BSV, which was higher in the nonparametric model. The parameter estimates are displayed in <xref rid="app1-pharmaceutics-13-02170" ref-type="app">Supplementary Table S1</xref>.</p></sec><sec id="sec2dot2-pharmaceutics-13-02170"><title>2.2. Population Used for Modeling</title><p>The models were built using imipenem PK data of 26 critically ill patients from a previously published prospective cohort study [<xref rid="B20-pharmaceutics-13-02170" ref-type="bibr">20</xref>] in the intensive care unit (ICU) of the Geneva University Hospitals (Geneva, Switzerland). Inclusion criteria were suspected or documented severe bacterial infection and age between 18 and 60 years. Exclusion criteria were estimated glomerular filtration rate (eGFR) &lt; 60 mL/min (measured by the Cockcroft&#8211;Gault equation [<xref rid="B21-pharmaceutics-13-02170" ref-type="bibr">21</xref>]), Body Mass Index (BMI) &lt; 18 or &gt;30 kg/m<sup>2</sup>, and pregnancy. None of the patients received continuous renal replacement therapy (CRRT). None of the patients used probenecid, which is the only drug that is known to influence imipenem concentrations [<xref rid="B22-pharmaceutics-13-02170" ref-type="bibr">22</xref>]. The usual dosing regimen for imipenem/cilastatin was 500 mg/500 mg every 6 h, administered by intermittent intravenous infusion for 30 min. </p><p>Peak (approximately 15&#8211;30 min after end of infusion), intermediate (midway between two sequential administrations), and trough (approximately 15 min before the next dose) blood samples (<italic toggle="yes">n</italic> = 138) were collected on days 1, 2, 3, 4, and/or 6 of therapy; 47% was drawn on the second day. After centrifugation of the blood, MOPS [3-(<italic toggle="yes">N</italic>-morpholino)propanesulfonic acid], a stabilizing buffer that protects imipenem from degradation [<xref rid="B23-pharmaceutics-13-02170" ref-type="bibr">23</xref>], was added to an equivalent volume of plasma. Imipenem plasma concentrations were analysed by high-performance liquid chromatography (HPLC), with ultraviolet (UV) detection at 298 nm. A median of three creatinine measures per patient were available.</p><p>Fewer than 10% [<xref rid="B24-pharmaceutics-13-02170" ref-type="bibr">24</xref>] of all concentrations (13/138 = 9.4%) were below the limit of quantification (0.5 mg/L) and were excluded from the popPK analysis. All concentrations above the LOQ (<italic toggle="yes">n</italic> = 125) were included for popPK analysis.</p></sec><sec id="sec2dot3-pharmaceutics-13-02170"><title>2.3. Population Used for Validation</title><p>The external dataset consisted of imipenem PK data of 19 critically ill patients from a previously published prospective randomized study [<xref rid="B25-pharmaceutics-13-02170" ref-type="bibr">25</xref>] in the ICU of the General University Hospital (Prague, Czech Republic). Inclusion criteria were hospital acquired pneumoniae (HAP) and age above 18 years. Exclusion criteria were carbapenem allergy, hepatic dysfunction (total serum bilirubin &gt; 27 &#956;mol/L), neutropenia (granulocytes &lt; 500/mm<sup>3</sup>), acute or chronic renal failure (serum creatinine &gt; 280 &#956;mol/L or CRRT), obesity (BMI &gt; 35 kg/m<sup>2</sup> or weight &gt; 110 kg), and pregnancy. None of the patients used probenecid.</p><p>Patients were randomized to receive either short infusion (bolus group) or extended infusion (extended group) of imipenem/cilastatin. Patients in the bolus group received 1 g/1 g imipenem/cilastatin every 8 h, administered by intermittent intravenous infusion for 30 min. Patients in the extended group received an initial loading dose of 1 g/1 g imipenem/cilastatin over 30 min, followed by an infusion of 500 mg/500 mg imipenem/cilastatin administered over 3 h every 6 h.</p><p>Blood samples (<italic toggle="yes">n</italic> = 114) were drawn on the second day of therapy: one sample prior to infusion and then at 0.33, 0.67, 4, 6, and 8 h (bolus group) or 2, 3.17, 4, 5, and 6 h (extended group). After centrifugation, MOPS buffer was added to an equivalent volume of plasma. Imipenem plasma concentrations were analysed by HPLC-UV at 313 nm. One creatinine measure per patient was available.</p><p>Fewer than 10% [<xref rid="B24-pharmaceutics-13-02170" ref-type="bibr">24</xref>] of all concentrations (3/114 = 2.6%) were below the limit of quantification (0.26 mg/L) and were excluded from analysis. All concentrations above the LOQ (<italic toggle="yes">n</italic> = 111) were included for analysis.</p></sec><sec id="sec2dot4-pharmaceutics-13-02170"><title>2.4. External Validation</title><p>Imipenem concentrations of the external validation database were predicted using the parametric and nonparametric models. Subsequently, the prediction errors (individual predicted concentration minus observed concentration) and relative prediction errors (prediction error/observed concentration) were calculated. The prediction errors were also calculated using Monte Carlo simulations (<italic toggle="yes">n</italic> = 1000) of both models.</p><p>To visualize the external validation, plots with predicted versus observed concentrations and visual predictive checks (VPCs) were generated. For each VPC, a set of 1000 simulated datasets (using one of the popPK models developed with the modeling population) was created to compare the observed concentrations of the external validation database with the distribution of the simulated concentrations. Stratification on dose (500 mg and 1000 mg) and eGFR (measured by the CKD-EPI equation unadjusted for BSA) was applied. For eGFR, stratification in three groups (19&#8211;46, 50&#8211;89, and 90&#8211;178 mL/min) and two groups (19&#8211;59 and 79&#8211;178 mL/min) was performed. These ranges were chosen to create equal groups.</p></sec><sec id="sec2dot5-pharmaceutics-13-02170"><title>2.5. Simulations</title><p>Monte Carlo simulations were performed using the final models. The three imipenem dosing regimens from the package insert [<xref rid="B22-pharmaceutics-13-02170" ref-type="bibr">22</xref>,<xref rid="B26-pharmaceutics-13-02170" ref-type="bibr">26</xref>] were evaluated: 500 mg every 6 h (q6h), 1000 mg every 8 h (q8h), and 1000 mg q6h, each for a predefined eGFR (measured by the CKD-EPI equation unadjusted for BSA) of 150, 120, and 90 mL/min. The infusion rate was 1000 mg/h for each dosing regimen. Five thousand subjects were simulated for each combination of dosing regimen and eGFR. For each simulated concentration&#8211;time profile, the <italic toggle="yes">f</italic>T <sub>&gt; MIC</sub> was calculated for MICs of 0.015&#8211;64 mg/L. The unbound imipenem concentrations were calculated from the total concentration using a fixed value for protein binding of 20% [<xref rid="B22-pharmaceutics-13-02170" ref-type="bibr">22</xref>]. Subsequently, the probability of target attainment (PTA) for 50% and 100% <italic toggle="yes">f</italic>T <sub>&gt; MIC</sub> was calculated. A PTA threshold of 97.5% [<xref rid="B3-pharmaceutics-13-02170" ref-type="bibr">3</xref>] was chosen.</p></sec><sec id="sec2dot6-pharmaceutics-13-02170"><title>2.6. Software</title><p>Parametric population PK modeling and simulation was performed using NONMEM (version 7.2, ICON Development Solutions, Ellicott City, MD, USA), Intel Visual Fortran Compiler XE 14.0 (Santa Clara, CA, USA), RStudio (version 1.1.456; RStudio, Boston, MA, USA, 2018), R (version 3.5.1; R foundation, Vienna, Austria, 2018), XPose (version 4.6.1; Uppsala University, Department of Pharmaceutical Biosciences, Uppsala, Sweden, 2018), PsN (version 4.6.0; Uppsala University, Department of Pharmaceutical Biosciences, Uppsala, Sweden, 2016), and Pirana [<xref rid="B27-pharmaceutics-13-02170" ref-type="bibr">27</xref>] (version 2.9.4; Certara, Princeton, NJ, USA, 2018). The <italic toggle="yes">f</italic>T <sub>&gt; MIC</sub> and PTA were calculated using Excel 2013.</p><p>Nonparametric population PK modeling, simulation, and calculation of <italic toggle="yes">f</italic>T <sub>&gt; MIC</sub> and PTA was performed using Pmetrics version 1.5.2 (Laboratory of Applied Pharmacokinetics and Bioinformatics, Los Angeles, CA, USA) [<xref rid="B28-pharmaceutics-13-02170" ref-type="bibr">28</xref>], Intel Visual Fortran Compiler XE 14.0 (Santa Clara, CA, USA), RStudio (version 1.1.456), and R (version 3.5.1). The raw VPC data were imported from Pmetrics into PsN (version 4.6.0) using the Pirana interface [<xref rid="B27-pharmaceutics-13-02170" ref-type="bibr">27</xref>] to generate VPCs with the same layout as NONMEM. VPC plots were subsequently created using XPose (version 4.6.1) within RStudio (version 1.1.456).</p></sec></sec><sec sec-type="results" id="sec3-pharmaceutics-13-02170"><title>3. Results</title><sec id="sec3dot1-pharmaceutics-13-02170"><title>3.1. Population</title><p>Demographic and clinical characteristics of the population (<italic toggle="yes">n</italic> = 26) used to build the popPK models and of the validation population (<italic toggle="yes">n</italic> = 19) are summarized in <xref rid="pharmaceutics-13-02170-t001" ref-type="table">Table 1</xref>. None of the patients received continuous renal replacement therapy (CRRT). The medians of the APACHE II score and age were higher in the validation group compared to the modeling population. The median eGFR was lower in the validation group. Six validation subjects had an absolute CKD-EPI eGFR lower than the minimum of 51 mL/min in the modeling group, while one validation subject had an eGFR above the maximum of 172 mL/min in the modeling population. The other characteristics were comparable between the two groups.</p></sec><sec id="sec3dot2-pharmaceutics-13-02170"><title>3.2. External Validation</title><p>The graphs of individual and population predicted concentrations plotted against the observed concentrations of the external dataset (<xref rid="pharmaceutics-13-02170-f001" ref-type="fig">Figure 1</xref>) were comparable for the two models. Both models showed good predictive performance for 500 mg as well as 1000 mg, except for concentrations higher than approximately 20 mg/L for the 1000 mg dose (see also the visual predictive checks (VPCs) in <xref rid="pharmaceutics-13-02170-f002" ref-type="fig">Figure 2</xref>). The same deviation of the peak concentration was still shown in VPCs without samples during infusion (data not shown).</p><p>The VPCs with eGFR stratification on three groups were unclear due to the small group size (data not shown). Stratification on the two eGFR groups was better, but the VPC plots are still not optimal due to the different sampling times of both dosing groups, which were equally distributed among the eGFR groups (see <xref rid="pharmaceutics-13-02170-f002" ref-type="fig">Figure 2</xref>). The individual plots in <xref rid="pharmaceutics-13-02170-f001" ref-type="fig">Figure 1</xref> and <xref rid="pharmaceutics-13-02170-f002" ref-type="fig">Figure 2</xref>, with stratification on the two eGFR groups, show that the predictive performance for eGFRs of 19&#8211;59 mL/min (<italic toggle="yes">n</italic> = 9) was worse than for eGFRs of 79&#8211;178 mL/min (<italic toggle="yes">n</italic> = 10). The VPCs show that both models predict too high concentrations for the trough levels of the low eGFR group. The median relative prediction error (<xref rid="pharmaceutics-13-02170-t002" ref-type="table">Table 2</xref>) was higher for trough levels in the low eGFR group (parametric: 83% and nonparametric: 88%) than in the high eGFR group (&#8722;24% and &#8722;19%). These prediction errors were comparable for the 500 mg and 1000 mg in each eGFR group (data not shown).</p><p>The median prediction error and median relative prediction error after 1000 simulations were similar to the single external validation for both models (<xref rid="pharmaceutics-13-02170-t002" ref-type="table">Table 2</xref>), although the 97.5&#8211;2.5% range is larger after the simulations using the nonparametric model. The wider distribution of the nonparametric model is also shown in the VPCs in <xref rid="pharmaceutics-13-02170-f002" ref-type="fig">Figure 2</xref>.</p><p>The proportion of observations between the 5th and 95th simulated percentiles in the VPCs in <xref rid="pharmaceutics-13-02170-f002" ref-type="fig">Figure 2</xref> are: 96% (Ia), 95% (IIa), 94% (IIIa), 81% (IVa), 88% (Va), 96% (Ib), 97% (IIb), 96% (IIIb), 81% (IVb), and 95% (Vb).</p></sec><sec id="sec3dot3-pharmaceutics-13-02170"><title>3.3. Simulations</title><p>The highest MICs with a probability of target attainment (PTA) &gt;97.5% for a target of 50% and 100% <italic toggle="yes">f</italic>T <sub>&gt; MIC</sub> attained by several imipenem dosing regimens and eGFR values of 150, 120, 90 mL/min are shown in <xref rid="pharmaceutics-13-02170-t003" ref-type="table">Table 3</xref> for both models. Fifty percent of the MICs calculated using the parametric model were equal to those calculated by the nonparametric model and the other half of the MICs were lower for the nonparametric model. The PTAs for the full MIC profile from 0.015 to 64 mg/L are shown in <xref rid="app1-pharmaceutics-13-02170" ref-type="app">Supplementary Table S2</xref>.</p></sec></sec><sec sec-type="discussion" id="sec4-pharmaceutics-13-02170"><title>4. Discussion</title><p>The external validation of parametric and nonparametric popPK models of imipenem in critically ill patients showed that the predictive performance of both models was sufficient in patients with high eGFRs (79&#8211;178 mL/min). However, the models could not be extrapolated to patients with lower eGFRs, as they were hardly included in the population used to build the model. The PTA simulations using both models were therefore performed for eGFR &#8805; 90 mL/min only. Fifty percent of the PTA calculations resulted in similar MICs for both models, while the other half of the simulations resulted in lower MICs for the nonparametric model.</p><p>Our external validation simulations showed that the median PE and RPE were comparable for both models, although the ranges of the PE and RPE were wider for the nonparametric model. This was also shown in the VPCs and can be explained by the higher BSV in the nonparametric model. In contrast to the external validation simulations, the original external validation (without simulations) showed higher medians of the PE and RPE for the nonparametric model. However, the mean PEs (&#8722;1.9 mg/L parametric and &#8211;1.8 mg/L nonparametric) were similar. Given the similar external validation simulation results, this deviation of median PEs and RPEs might be caused by the small study size.</p><p>The poor predictive performance for low eGFRs can be explained by the paucity of subjects with renal impairment in the modeling population. Only 1 of 26 patients in the modeling population (<italic toggle="yes">n</italic> = 26) had an eGFR lower than 90 mL/min, while this applied to 12 of 19 patients in the validation population. After the external validation showed that both popPK models could not be extrapolated to low eGFRs, we decided to perform the PTA simulations for eGFR &#8805; 90 mL/min only, deviating from the original plan to also simulate for lower eGFRs. The cut-off of 90 mL/min was chosen from a practical point of view, in line with the package inserts [<xref rid="B22-pharmaceutics-13-02170" ref-type="bibr">22</xref>,<xref rid="B26-pharmaceutics-13-02170" ref-type="bibr">26</xref>] instead of the eGFR ranges from the VPCs (19&#8211;59 and 79&#8211;178 mL/min), which were chosen to create two equal groups. The popPK models are still applicable to a high proportion of critically ill patients. Augmented renal clearance (defined as increased renal elimination of circulating solutes and drugs as compared with normal baseline [<xref rid="B29-pharmaceutics-13-02170" ref-type="bibr">29</xref>]) has been reported in approximately 30&#8211;65% of critically ill patients [<xref rid="B30-pharmaceutics-13-02170" ref-type="bibr">30</xref>].</p><p>The VPCs stratified on dose showed for both models a good predictive performance for the 500 and 1000 mg regimens, except for peak concentrations (C<sub>max</sub>) for the 1000 mg dose. This dose could not be tested during popPK modeling because the modeling population only used 500 mg. The higher than predicted C<sub>max</sub> is not likely to be explained by non-linear PK [<xref rid="B22-pharmaceutics-13-02170" ref-type="bibr">22</xref>,<xref rid="B31-pharmaceutics-13-02170" ref-type="bibr">31</xref>]. The most probable reasons for the C<sub>max</sub> deviation are the critical timing of the peak samples and the variable PK in critically ill patients [<xref rid="B32-pharmaceutics-13-02170" ref-type="bibr">32</xref>], which is also shown by others [<xref rid="B31-pharmaceutics-13-02170" ref-type="bibr">31</xref>,<xref rid="B33-pharmaceutics-13-02170" ref-type="bibr">33</xref>,<xref rid="B34-pharmaceutics-13-02170" ref-type="bibr">34</xref>,<xref rid="B35-pharmaceutics-13-02170" ref-type="bibr">35</xref>]. However, it is important to realize that, instead of C<sub>max</sub>, the trough level is relevant for the targets of 50&#8211;100% <italic toggle="yes">f</italic>T <sub>&gt; MIC</sub>. Importantly, the simulations did not show different prediction errors for trough levels after 500 mg and 1000 mg. Therefore, we decided to include 1000 mg dose regimens in the PTA simulations.</p><p>Our external validation findings emphasise the importance of such a validation when popPK models are used to optimize dosing strategies based on PTA simulations, or to individualize dosing by therapeutic drug monitoring software. PopPK model publications often not include external validation. A survey of the literature revealed that only for 7% of popPK models published between 2002 and 2004 (<italic toggle="yes">n</italic> = 324) was an external evaluation performed [<xref rid="B36-pharmaceutics-13-02170" ref-type="bibr">36</xref>]. To our knowledge, a more recent survey does not exist.</p><p>Our simulations showed that 50% of the PTA results were comparable for both models, while the other half resulted in lower MICs for the nonparametric model, although the majority (7/9 = 78%) differed by only one dilution. The lower MICs could be caused by a higher estimated BSV of the popPK parameter values in the nonparametric model, leading to a wider range of concentrations. It is impossible to judge which of the models represents the &#8220;truth&#8221;. The parametric model could have included too little variability or the nonparametric model could be too flexible. Probably, the truth is somewhere in between. We compared our simulation results with other published M&amp;S studies of imipenem in critically ill patients, of which one was based on a parametric model [<xref rid="B15-pharmaceutics-13-02170" ref-type="bibr">15</xref>] and two on nonparametric models [<xref rid="B16-pharmaceutics-13-02170" ref-type="bibr">16</xref>,<xref rid="B17-pharmaceutics-13-02170" ref-type="bibr">17</xref>]. Despite differences in parameter estimates, our finding of higher MICs with the parametric model was confirmed by these papers [<xref rid="B15-pharmaceutics-13-02170" ref-type="bibr">15</xref>,<xref rid="B16-pharmaceutics-13-02170" ref-type="bibr">16</xref>,<xref rid="B17-pharmaceutics-13-02170" ref-type="bibr">17</xref>]. Similar to two studies [<xref rid="B15-pharmaceutics-13-02170" ref-type="bibr">15</xref>,<xref rid="B17-pharmaceutics-13-02170" ref-type="bibr">17</xref>], we showed that it is difficult to reach high MICs from 1 mg/L with an increased target of 100% <italic toggle="yes">f</italic>T <sub>&gt; MIC</sub>, which confirms again that more prospective studies about the required target of beta-lactams in critically ill patients are needed. The regression analysis of the original study [<xref rid="B20-pharmaceutics-13-02170" ref-type="bibr">20</xref>], with four beta-lactams from which we analysed a subgroup, did not find a significant association between clinical failure and trough levels below 2 mg/L, indicating that an elevated target of 100% <italic toggle="yes">f</italic>T <sub>&gt; MIC</sub> might not be necessary in this population. Even a larger study was underpowered to find a significant association between clinical failure and troughs below 2 mg/L [<xref rid="B19-pharmaceutics-13-02170" ref-type="bibr">19</xref>]. Importantly, the latter study [<xref rid="B19-pharmaceutics-13-02170" ref-type="bibr">19</xref>] proved that fear about toxicity at high doses of 3&#8211;4 g/day is unnecessary, as patients receiving these doses did not have increased toxicity compared to the standard dose of 2 g/day.</p><p>Based on the 50% <italic toggle="yes">f</italic>T <sub>&gt; MIC</sub> target simulations, we conclude that a high dose of 1000 mg q6h is required to maximize the probability to reach MICs of 2 mg/L (e.g., for <italic toggle="yes">Enterobacterales</italic> [<xref rid="B37-pharmaceutics-13-02170" ref-type="bibr">37</xref>]) in critically ill patients with eGFRs of 90&#8211;120 mL/min, although the PTAs using the nonparametric model were below the 97.5% cut-off but still above 90% (see <xref rid="app1-pharmaceutics-13-02170" ref-type="app">Supplementary Table S2</xref>). This is in line with the American prescribing information [<xref rid="B26-pharmaceutics-13-02170" ref-type="bibr">26</xref>]. However, they recommend this dosing regimen also for MICs of 4 mg/L (e.g., for <italic toggle="yes">Pseudomonas aeruginosa</italic>), similar to the European product characteristics [<xref rid="B22-pharmaceutics-13-02170" ref-type="bibr">22</xref>], although these brochures are of course not specifically dedicated to critically ill patients. Considering our simulation results, it is difficult to give dosing recommendations for MICs of 4 mg/L, and also for higher MICs of 2 mg/L and eGFRs of 150 mL/min, because the PTA values differ largely per modeling approach. For example, for 1000 mg q6h, eGFR 90, 50% <italic toggle="yes">f</italic>T <sub>&gt; MIC</sub>, and MIC 4 mg/L, the PTA was 90% for the parametric model and 63% for the nonparametric model (see also <xref rid="app1-pharmaceutics-13-02170" ref-type="app">Supplementary Table S2</xref>). Dosing regimens may look acceptable following the parametric model, while the nonparametric model might plead for increased dosing. As previously stated, the truth may be somewhere in between. One of the objectives of our study was to determine which of the two previously described imipenem models delivers the best Bayesian posterior estimates to predict the imipenem concentrations in an external independent database. It was not possible to assign a winner, because the external predictive performance of both models was adequate. However, as the dosing simulations based on the models show different results, more research on this topic is clearly needed. Until now, we recommend all readers of M&amp;S papers to be aware of the consequences of the chosen modeling approach before implementing the dosing recommendations of these papers in clinical practice.</p><p>Few studies comparing parametric and nonparametric M&amp;S are available in the literature. Precluding the studies with currently outdated software [<xref rid="B38-pharmaceutics-13-02170" ref-type="bibr">38</xref>,<xref rid="B39-pharmaceutics-13-02170" ref-type="bibr">39</xref>,<xref rid="B40-pharmaceutics-13-02170" ref-type="bibr">40</xref>,<xref rid="B41-pharmaceutics-13-02170" ref-type="bibr">41</xref>], we found eight comparison studies [<xref rid="B42-pharmaceutics-13-02170" ref-type="bibr">42</xref>,<xref rid="B43-pharmaceutics-13-02170" ref-type="bibr">43</xref>,<xref rid="B44-pharmaceutics-13-02170" ref-type="bibr">44</xref>,<xref rid="B45-pharmaceutics-13-02170" ref-type="bibr">45</xref>,<xref rid="B46-pharmaceutics-13-02170" ref-type="bibr">46</xref>,<xref rid="B47-pharmaceutics-13-02170" ref-type="bibr">47</xref>,<xref rid="B48-pharmaceutics-13-02170" ref-type="bibr">48</xref>,<xref rid="B49-pharmaceutics-13-02170" ref-type="bibr">49</xref>]. For three of these studies, the parameters of both models could not be compared due to a different model structure [<xref rid="B42-pharmaceutics-13-02170" ref-type="bibr">42</xref>,<xref rid="B43-pharmaceutics-13-02170" ref-type="bibr">43</xref>] or unreported values [<xref rid="B46-pharmaceutics-13-02170" ref-type="bibr">46</xref>]. The majority of the remaining five comparison studies showed comparable parameter estimates of both models [<xref rid="B45-pharmaceutics-13-02170" ref-type="bibr">45</xref>,<xref rid="B47-pharmaceutics-13-02170" ref-type="bibr">47</xref>,<xref rid="B48-pharmaceutics-13-02170" ref-type="bibr">48</xref>,<xref rid="B49-pharmaceutics-13-02170" ref-type="bibr">49</xref>], although the BSV of the parametric estimates was often higher for the nonparametric model [<xref rid="B44-pharmaceutics-13-02170" ref-type="bibr">44</xref>,<xref rid="B45-pharmaceutics-13-02170" ref-type="bibr">45</xref>,<xref rid="B47-pharmaceutics-13-02170" ref-type="bibr">47</xref>], similar to our findings. The three comparison studies that performed an external validation of both models concluded that the nonparametric models provided the lowest relative prediction error (RPE) for concentrations [<xref rid="B46-pharmaceutics-13-02170" ref-type="bibr">46</xref>] and area under the curve [<xref rid="B43-pharmaceutics-13-02170" ref-type="bibr">43</xref>,<xref rid="B44-pharmaceutics-13-02170" ref-type="bibr">44</xref>], although for one of the latter studies [<xref rid="B44-pharmaceutics-13-02170" ref-type="bibr">44</xref>], the RPE of the concentrations was similar. Our external validation showed a comparable RPE for both models after simulations, reflecting a good predictive performance of both models. PTA calculations using both modeling approaches were only performed by one previous study [<xref rid="B48-pharmaceutics-13-02170" ref-type="bibr">48</xref>], which concluded that the PTA versus MIC profiles (based on 10,000 simulations) were similar. This seems to be caused by the similar parameter estimates and BSV of these models. Contrary to the latter study, our PTA simulations show different results for both modeling approaches, which could be explained by the higher BSV of our nonparametric model.</p><p>This paper has a few limitations. The main limitation is that the modeling population did not include 1000 mg dose regimens as well as patients with impaired renal function. A drawback of the validation population was that only 12 patients matched the eGFR range of the modeling population (51&#8211;172 mL/min). Another limitation is that the simulations were performed with a fixed value of protein binding because only total drug concentrations were available. However, the consequences seem to be low given the small protein binding of 20% [<xref rid="B22-pharmaceutics-13-02170" ref-type="bibr">22</xref>]. </p></sec><sec sec-type="conclusions" id="sec5-pharmaceutics-13-02170"><title>5. Conclusions</title><p>The external predictive performance of parametric and nonparametric popPK models of imipenem in critically ill patients was adequate for subjects with high eGFRs, but insufficient for low eGFRs. This was explained by a paucity of subjects with renal impairment in the modeling population. External validation of popPK models is important to test the possibility of extrapolation to other populations. The PTA simulations of both models indicated that 1000 mg q6h is suitable to reach MICs of 2 mg/L in critically ill patients with eGFRs of 90&#8211;120 mL/min. However, for MICs of 2 mg/L and an eGFR of 150 mL/min, and for MICs of 4 mg/L, dosing recommendations could not be given because the PTA values differed largely per modeling approach. The consequences of the different modeling approaches in clinical practice should be further investigated.</p></sec></body><back><ack><title>Acknowledgments</title><p>The authors thank Johan W. Mouton for his contribution to the study design and all inspiring discussions about the data interpretation. Unfortunately, he was not able to read the first version of the manuscript. We are very sad that Mouton passed away on 9 July 2019. We thank Elodie von Dach (Geneva University Hospitals) for her extensive work recruiting patients and entering the data. Full membership of the COMBACTE-NET Consortium is available on the website: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.combacte.com/about/about-combacte-net-detail/">https://www.combacte.com/about/about-combacte-net-detail/</uri> (accessed on 8 November 2021).</p></ack><fn-group><fn><p><bold>Publisher&#8217;s Note:</bold> MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><app-group><app id="app1-pharmaceutics-13-02170"><title>Supplementary Materials</title><p>The following are available online at <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.mdpi.com/article/10.3390/pharmaceutics13122170/s1">https://www.mdpi.com/article/10.3390/pharmaceutics13122170/s1</uri>, Table S1: Population parameter estimates; Table S2: Probabilities of target attainment (PTA) simulations.</p><supplementary-material id="pharmaceutics-13-02170-s001" position="float" content-type="local-data" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pharmaceutics-13-02170-s001.zip" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>Conceptualization, F.d.V., B.C.M.d.W., M.N.N., J.S., W.M.Y., S.H., A.H., T.v.G., B.C.P.K. and A.E.M.; acquisition of data, J.S., S.H. and A.H.; formal analysis, F.d.V., B.C.M.d.W., T.v.G., B.C.P.K. and A.E.M.; writing&#8212;original draft preparation, F.d.V.; writing&#8212;review and editing, B.C.M.d.W., M.N.N., J.S., W.M.Y., S.H., A.H., T.v.G., B.C.P.K. and A.E.M. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Funding</title><p>This research was funded by the Innovative Medicines Initiative Joint Undertaking under grant agreement no. [115523], resources of which are composed of financial contribution from the European Union&#8217;s Seventh Framework Programme (FP7/2007&#8211;2013) and EFPIA companies&#8217; in-kind contribution. The research leading to these results was conducted as part of the COMBACTE-NET consortium. For further information please refer to <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.combacte.com/">http://www.combacte.com/</uri>, accessed on 8 November 2021. The popPK models were developed using data of a cohort study funded by a Research and Development Grant awarded by the Geneva University Hospitals in 2009 [PRD 09-II-025]. AH was partially supported by the EU-funded project AIDA [grant Health-F3-2011-278348]. The external validation was performed using data of a study supported by the Internal Grant Agency of Palacky University (Olomouc, Czech Republic) [IGA UPOL2014 LF 008].</p></notes><notes><title>Institutional Review Board Statement</title><p>The study performed in the Geneva University Hospitals was conducted according to the guidelines of the Declaration of Helsinki and approved by the Geneva University Hospitals Ethics Committee (NAC 09-117). The study performed in the General University Hospital of Prague was conducted according to the guidelines of the Declaration of Helsinki, and approved by the local institutional Research Ethics Committee of General University Hospital (Prague, Czech Republic) [no. 1547/09 S-IV].</p></notes><notes><title>Informed Consent Statement</title><p>For the study performed in the Geneva University Hospitals, the Ethics Committee waived the requirement for informed consent from patients who were unconscious or otherwise unable to understand the study protocol, given its observational nature. For the study performed in the General University Hospital of Prague, written informed consent was not required from the subjects prior to inclusion because both regimens are considered standard clinical practice, but a subsequent written consent for analysis of the data was obtained from the subjects after recovery from unconsciousness.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>The data presented in this study are available on request from the corresponding author. The data are not publicly available due to controlled access requirements for clinical trial data.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>F.d.V., B.C.M.d.W., M.N.N., J.S., A.H. and A.E.M. declare that they have no conflict of interest. B.K. has received research funding from ZonMw (Dutch governmental support) and Teva. S.H. has received honoraria from Sandoz for participation in a Scientific Advisory Board. T.v.G. has received honoraria as consultant/speaker from Aurinia Pharma, Vitaeris, Roche Diagnostics, Novartis, Astellas, and Chiesi, and grant support for transplant related studies from Chiesi and Astellas. None of the EFPIA partners involved in the COMBACTE-NET consortium have a conflict of interest; none of them contributed to this article.</p></notes><ref-list><title>References</title><ref id="B1-pharmaceutics-13-02170"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mouton</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Ambrose</surname><given-names>P.G.</given-names></name><name name-style="western"><surname>Canton</surname><given-names>R.</given-names></name><name name-style="western"><surname>Drusano</surname><given-names>G.L.</given-names></name><name name-style="western"><surname>Harbarth</surname><given-names>S.</given-names></name><name name-style="western"><surname>MacGowan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Theuretzbacher</surname><given-names>U.</given-names></name><name name-style="western"><surname>Turnidge</surname><given-names>J.</given-names></name></person-group><article-title>Conserving antibiotics for the future: New ways to use old and new drugs from a pharmacokinetic and pharmacodynamic perspective</article-title><source>Drug Resist. Updates</source><year>2011</year><volume>14</volume><fpage>107</fpage><lpage>117</lpage><pub-id pub-id-type="doi">10.1016/j.drup.2011.02.005</pub-id><pub-id pub-id-type="pmid">21440486</pub-id></element-citation></ref><ref id="B2-pharmaceutics-13-02170"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Velde</surname><given-names>F.</given-names></name><name name-style="western"><surname>Mouton</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>de Winter</surname><given-names>B.C.M.</given-names></name><name name-style="western"><surname>van Gelder</surname><given-names>T.</given-names></name><name name-style="western"><surname>Koch</surname><given-names>B.C.P.</given-names></name></person-group><article-title>Clinical applications of population pharmacokinetic models of antibiotics: Challenges and perspectives</article-title><source>Pharmacol. Res.</source><year>2018</year><volume>134</volume><fpage>280</fpage><lpage>288</lpage><pub-id pub-id-type="doi">10.1016/j.phrs.2018.07.005</pub-id><pub-id pub-id-type="pmid">30033398</pub-id></element-citation></ref><ref id="B3-pharmaceutics-13-02170"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mouton</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>D.F.</given-names></name><name name-style="western"><surname>Apfalter</surname><given-names>P.</given-names></name><name name-style="western"><surname>Canton</surname><given-names>R.</given-names></name><name name-style="western"><surname>Giske</surname><given-names>C.G.</given-names></name><name name-style="western"><surname>Ivanova</surname><given-names>M.</given-names></name><name name-style="western"><surname>MacGowan</surname><given-names>A.P.</given-names></name><name name-style="western"><surname>Rodloff</surname><given-names>A.</given-names></name><name name-style="western"><surname>Soussy</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Steinbakk</surname><given-names>M.</given-names></name><etal/></person-group><article-title>The role of pharmacokinetics/pharmacodynamics in setting clinical MIC breakpoints: The EUCAST approach</article-title><source>Clin. Microbiol. Infect.</source><year>2012</year><volume>18</volume><fpage>E37</fpage><lpage>E45</lpage><pub-id pub-id-type="doi">10.1111/j.1469-0691.2011.03752.x</pub-id><pub-id pub-id-type="pmid">22264314</pub-id></element-citation></ref><ref id="B4-pharmaceutics-13-02170"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Racine-Poon</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wakefield</surname><given-names>J.</given-names></name></person-group><article-title>Statistical methods for population pharmacokinetic modelling</article-title><source>Stat. Methods Med. Res.</source><year>1998</year><volume>7</volume><fpage>63</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1177/096228029800700106</pub-id><pub-id pub-id-type="pmid">9533262</pub-id></element-citation></ref><ref id="B5-pharmaceutics-13-02170"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tatarinova</surname><given-names>T.</given-names></name><name name-style="western"><surname>Neely</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bartroff</surname><given-names>J.</given-names></name><name name-style="western"><surname>van Guilder</surname><given-names>M.</given-names></name><name name-style="western"><surname>Yamada</surname><given-names>W.</given-names></name><name name-style="western"><surname>Bayard</surname><given-names>D.</given-names></name><name name-style="western"><surname>Jelliffe</surname><given-names>R.</given-names></name><name name-style="western"><surname>Leary</surname><given-names>R.</given-names></name><name name-style="western"><surname>Chubatiuk</surname><given-names>A.</given-names></name><name name-style="western"><surname>Schumitzky</surname><given-names>A.</given-names></name></person-group><article-title>Two general methods for population pharmacokinetic modeling: Non-parametric adaptive grid and non-parametric Bayesian</article-title><source>J. Pharmacokinet. Pharmacodyn.</source><year>2013</year><volume>40</volume><fpage>189</fpage><lpage>199</lpage><pub-id pub-id-type="doi">10.1007/s10928-013-9302-8</pub-id><pub-id pub-id-type="pmid">23404393</pub-id><pub-id pub-id-type="pmcid">PMC3630269</pub-id></element-citation></ref><ref id="B6-pharmaceutics-13-02170"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Velde</surname><given-names>F.</given-names></name><name name-style="western"><surname>de Winter</surname><given-names>B.C.M.</given-names></name><name name-style="western"><surname>Neely</surname><given-names>M.N.</given-names></name><name name-style="western"><surname>Yamada</surname><given-names>W.M.</given-names></name><name name-style="western"><surname>Koch</surname><given-names>B.C.P.</given-names></name><name name-style="western"><surname>Harbarth</surname><given-names>S.</given-names></name><name name-style="western"><surname>von Dach</surname><given-names>E.</given-names></name><name name-style="western"><surname>van Gelder</surname><given-names>T.</given-names></name><name name-style="western"><surname>Huttner</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mouton</surname><given-names>J.W.</given-names></name><etal/></person-group><article-title>Population Pharmacokinetics of Imipenem in Critically Ill Patients: A Parametric and Nonparametric Model Converge on CKD-EPI Estimated Glomerular Filtration Rate as an Impactful Covariate</article-title><source>Clin. Pharmacokinet.</source><year>2020</year><volume>59</volume><fpage>885</fpage><lpage>898</lpage><pub-id pub-id-type="doi">10.1007/s40262-020-00859-1</pub-id><pub-id pub-id-type="pmid">31956969</pub-id><pub-id pub-id-type="pmcid">PMC7329758</pub-id></element-citation></ref><ref id="B7-pharmaceutics-13-02170"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Levey</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Stevens</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Schmid</surname><given-names>C.H.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.L.</given-names></name><name name-style="western"><surname>Castro</surname><given-names>A.F.</given-names><suffix>3rd</suffix></name><name name-style="western"><surname>Feldman</surname><given-names>H.I.</given-names></name><name name-style="western"><surname>Kusek</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Eggers</surname><given-names>P.</given-names></name><name name-style="western"><surname>Van Lente</surname><given-names>F.</given-names></name><name name-style="western"><surname>Greene</surname><given-names>T.</given-names></name><etal/></person-group><article-title>A new equation to estimate glomerular filtration rate</article-title><source>Ann. Intern. Med.</source><year>2009</year><volume>150</volume><fpage>604</fpage><lpage>612</lpage><pub-id pub-id-type="doi">10.7326/0003-4819-150-9-200905050-00006</pub-id><pub-id pub-id-type="pmid">19414839</pub-id><pub-id pub-id-type="pmcid">PMC2763564</pub-id></element-citation></ref><ref id="B8-pharmaceutics-13-02170"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ambrose</surname><given-names>P.G.</given-names></name><name name-style="western"><surname>Bhavnani</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Rubino</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Louie</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gumbo</surname><given-names>T.</given-names></name><name name-style="western"><surname>Forrest</surname><given-names>A.</given-names></name><name name-style="western"><surname>Drusano</surname><given-names>G.L.</given-names></name></person-group><article-title>Pharmacokinetics-pharmacodynamics of antimicrobial therapy: It&#8217;s not just for mice anymore</article-title><source>Clin. Infect. Dis.</source><year>2007</year><volume>44</volume><fpage>79</fpage><lpage>86</lpage><pub-id pub-id-type="doi">10.1086/510079</pub-id><pub-id pub-id-type="pmid">17143821</pub-id></element-citation></ref><ref id="B9-pharmaceutics-13-02170"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Crandon</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Luyt</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Aubry</surname><given-names>A.</given-names></name><name name-style="western"><surname>Chastre</surname><given-names>J.</given-names></name><name name-style="western"><surname>Nicolau</surname><given-names>D.P.</given-names></name></person-group><article-title>Pharmacodynamics of carbapenems for the treatment of Pseudomonas aeruginosa ventilator-associated pneumonia: Associations with clinical outcome and recurrence</article-title><source>J. Antimicrob. Chemother.</source><year>2016</year><volume>71</volume><fpage>2534</fpage><lpage>2537</lpage><pub-id pub-id-type="doi">10.1093/jac/dkw200</pub-id><pub-id pub-id-type="pmid">27272723</pub-id></element-citation></ref><ref id="B10-pharmaceutics-13-02170"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ariano</surname><given-names>R.E.</given-names></name><name name-style="western"><surname>Nyhlen</surname><given-names>A.</given-names></name><name name-style="western"><surname>Donnelly</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Sitar</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Harding</surname><given-names>G.K.</given-names></name><name name-style="western"><surname>Zelenitsky</surname><given-names>S.A.</given-names></name></person-group><article-title>Pharmacokinetics and pharmacodynamics of meropenem in febrile neutropenic patients with bacteremia</article-title><source>Ann. Pharmacother.</source><year>2005</year><volume>39</volume><fpage>32</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1345/aph.1E271</pub-id><pub-id pub-id-type="pmid">15598967</pub-id></element-citation></ref><ref id="B11-pharmaceutics-13-02170"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roberts</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Abdul-Aziz</surname><given-names>M.H.</given-names></name><name name-style="western"><surname>Lipman</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mouton</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Vinks</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Felton</surname><given-names>T.W.</given-names></name><name name-style="western"><surname>Hope</surname><given-names>W.W.</given-names></name><name name-style="western"><surname>Farkas</surname><given-names>A.</given-names></name><name name-style="western"><surname>Neely</surname><given-names>M.N.</given-names></name><name name-style="western"><surname>Schentag</surname><given-names>J.J.</given-names></name><etal/></person-group><article-title>Individualised antibiotic dosing for patients who are critically ill: Challenges and potential solutions</article-title><source>Lancet Infect. Dis.</source><year>2014</year><volume>14</volume><fpage>498</fpage><lpage>509</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(14)70036-2</pub-id><pub-id pub-id-type="pmid">24768475</pub-id><pub-id pub-id-type="pmcid">PMC4181663</pub-id></element-citation></ref><ref id="B12-pharmaceutics-13-02170"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>C.</given-names></name><name name-style="western"><surname>Du</surname><given-names>X.</given-names></name><name name-style="western"><surname>Kuti</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Nicolau</surname><given-names>D.P.</given-names></name></person-group><article-title>Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections</article-title><source>Antimicrob. Agents Chemother.</source><year>2007</year><volume>51</volume><fpage>1725</fpage><lpage>1730</lpage><pub-id pub-id-type="doi">10.1128/AAC.00294-06</pub-id><pub-id pub-id-type="pmid">17307978</pub-id><pub-id pub-id-type="pmcid">PMC1855547</pub-id></element-citation></ref><ref id="B13-pharmaceutics-13-02170"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Muller</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>Punt</surname><given-names>N.</given-names></name><name name-style="western"><surname>Mouton</surname><given-names>J.W.</given-names></name></person-group><article-title>Optimal exposures of ceftazidime predict the probability of microbiological and clinical outcome in the treatment of nosocomial pneumonia</article-title><source>J. Antimicrob. Chemother.</source><year>2013</year><volume>68</volume><fpage>900</fpage><lpage>906</lpage><pub-id pub-id-type="doi">10.1093/jac/dks468</pub-id><pub-id pub-id-type="pmid">23190766</pub-id></element-citation></ref><ref id="B14-pharmaceutics-13-02170"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Craig</surname><given-names>W.A.</given-names></name></person-group><article-title>Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men</article-title><source>Clin. Infect. Dis.</source><year>1998</year><volume>26</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1086/516284</pub-id><pub-id pub-id-type="pmid">9455502</pub-id></element-citation></ref><ref id="B15-pharmaceutics-13-02170"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Couffignal</surname><given-names>C.</given-names></name><name name-style="western"><surname>Pajot</surname><given-names>O.</given-names></name><name name-style="western"><surname>Laouenan</surname><given-names>C.</given-names></name><name name-style="western"><surname>Burdet</surname><given-names>C.</given-names></name><name name-style="western"><surname>Foucrier</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wolff</surname><given-names>M.</given-names></name><name name-style="western"><surname>Armand-Lefevre</surname><given-names>L.</given-names></name><name name-style="western"><surname>Mentre</surname><given-names>F.</given-names></name><name name-style="western"><surname>Massias</surname><given-names>L.</given-names></name></person-group><article-title>Population pharmacokinetics of imipenem in critically ill patients with suspected ventilator-associated pneumonia and evaluation of dosage regimens</article-title><source>Br. J. Clin. Pharmacol.</source><year>2014</year><volume>78</volume><fpage>1022</fpage><lpage>1034</lpage><pub-id pub-id-type="doi">10.1111/bcp.12435</pub-id><pub-id pub-id-type="pmid">24903189</pub-id><pub-id pub-id-type="pmcid">PMC4243876</pub-id></element-citation></ref><ref id="B16-pharmaceutics-13-02170"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sakka</surname><given-names>S.G.</given-names></name><name name-style="western"><surname>Glauner</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Bulitta</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Kinzig-Schippers</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pfister</surname><given-names>W.</given-names></name><name name-style="western"><surname>Drusano</surname><given-names>G.L.</given-names></name><name name-style="western"><surname>Sorgel</surname><given-names>F.</given-names></name></person-group><article-title>Population pharmacokinetics and pharmacodynamics of continuous versus short-term infusion of imipenem-cilastatin in critically ill patients in a randomized, controlled trial</article-title><source>Antimicrob. Agents Chemother.</source><year>2007</year><volume>51</volume><fpage>3304</fpage><lpage>3310</lpage><pub-id pub-id-type="doi">10.1128/AAC.01318-06</pub-id><pub-id pub-id-type="pmid">17620371</pub-id><pub-id pub-id-type="pmcid">PMC2043189</pub-id></element-citation></ref><ref id="B17-pharmaceutics-13-02170"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Suchankova</surname><given-names>H.</given-names></name><name name-style="western"><surname>Lips</surname><given-names>M.</given-names></name><name name-style="western"><surname>Urbanek</surname><given-names>K.</given-names></name><name name-style="western"><surname>Neely</surname><given-names>M.N.</given-names></name><name name-style="western"><surname>Strojil</surname><given-names>J.</given-names></name></person-group><article-title>Is continuous infusion of imipenem always the best choice?</article-title><source>Int. J. Antimicrob. Agents</source><year>2017</year><volume>49</volume><fpage>348</fpage><lpage>354</lpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2016.12.005</pub-id><pub-id pub-id-type="pmid">28189734</pub-id></element-citation></ref><ref id="B18-pharmaceutics-13-02170"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roberts</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Paul</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Akova</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bassetti</surname><given-names>M.</given-names></name><name name-style="western"><surname>De Waele</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Dimopoulos</surname><given-names>G.</given-names></name><name name-style="western"><surname>Kaukonen</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Koulenti</surname><given-names>D.</given-names></name><name name-style="western"><surname>Martin</surname><given-names>C.</given-names></name><name name-style="western"><surname>Montravers</surname><given-names>P.</given-names></name><etal/></person-group><article-title>DALI: Defining antibiotic levels in intensive care unit patients: Are current beta-lactam antibiotic doses sufficient for critically ill patients?</article-title><source>Clin. Infect. Dis.</source><year>2014</year><volume>58</volume><fpage>1072</fpage><lpage>1083</lpage><pub-id pub-id-type="doi">10.1093/cid/ciu027</pub-id><pub-id pub-id-type="pmid">24429437</pub-id></element-citation></ref><ref id="B19-pharmaceutics-13-02170"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bricheux</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lenggenhager</surname><given-names>L.</given-names></name><name name-style="western"><surname>Hughes</surname><given-names>S.</given-names></name><name name-style="western"><surname>Karmime</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lescuyer</surname><given-names>P.</given-names></name><name name-style="western"><surname>Huttner</surname><given-names>A.</given-names></name></person-group><article-title>Therapeutic drug monitoring of imipenem and the incidence of toxicity and failure in hospitalized patients: A retrospective cohort study</article-title><source>Clin. Microbiol. Infect.</source><year>2019</year><volume>25</volume><fpage>383.e1</fpage><lpage>383.e4</lpage><pub-id pub-id-type="doi">10.1016/j.cmi.2018.11.020</pub-id><pub-id pub-id-type="pmid">30528370</pub-id></element-citation></ref><ref id="B20-pharmaceutics-13-02170"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huttner</surname><given-names>A.</given-names></name><name name-style="western"><surname>Von Dach</surname><given-names>E.</given-names></name><name name-style="western"><surname>Renzoni</surname><given-names>A.</given-names></name><name name-style="western"><surname>Huttner</surname><given-names>B.D.</given-names></name><name name-style="western"><surname>Affaticati</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pagani</surname><given-names>L.</given-names></name><name name-style="western"><surname>Daali</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Pugin</surname><given-names>J.</given-names></name><name name-style="western"><surname>Karmime</surname><given-names>A.</given-names></name><name name-style="western"><surname>Fathi</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Augmented renal clearance, low beta-lactam concentrations and clinical outcomes in the critically ill: An observational prospective cohort study</article-title><source>Int. J. Antimicrob. Agents</source><year>2015</year><volume>45</volume><fpage>385</fpage><lpage>392</lpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2014.12.017</pub-id><pub-id pub-id-type="pmid">25656151</pub-id></element-citation></ref><ref id="B21-pharmaceutics-13-02170"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cockcroft</surname><given-names>D.W.</given-names></name><name name-style="western"><surname>Gault</surname><given-names>M.H.</given-names></name></person-group><article-title>Prediction of creatinine clearance from serum creatinine</article-title><source>Nephron</source><year>1976</year><volume>16</volume><fpage>31</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1159/000180580</pub-id><pub-id pub-id-type="pmid">1244564</pub-id></element-citation></ref><ref id="B22-pharmaceutics-13-02170"><label>22.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>Merck Sharp &amp; Dohme BV</collab></person-group><article-title>Summary of Product Characteristics Tienam 500/500mg Powder for Solution for Infusion</article-title><publisher-loc>Haarlem, The Netherlands</publisher-loc><year>2020</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.geneesmiddeleninformatiebank.nl/smpc/h11089_smpc.pdf" ext-link-type="uri">https://www.geneesmiddeleninformatiebank.nl/smpc/h11089_smpc.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2021-11-08">(accessed on 8 November 2021)</date-in-citation></element-citation></ref><ref id="B23-pharmaceutics-13-02170"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Legrand</surname><given-names>T.</given-names></name><name name-style="western"><surname>Chhun</surname><given-names>S.</given-names></name><name name-style="western"><surname>Rey</surname><given-names>E.</given-names></name><name name-style="western"><surname>Blanchet</surname><given-names>B.</given-names></name><name name-style="western"><surname>Zahar</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Lanternier</surname><given-names>F.</given-names></name><name name-style="western"><surname>Pons</surname><given-names>G.</given-names></name><name name-style="western"><surname>Jullien</surname><given-names>V.</given-names></name></person-group><article-title>Simultaneous determination of three carbapenem antibiotics in plasma by HPLC with ultraviolet detection</article-title><source>J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.</source><year>2008</year><volume>875</volume><fpage>551</fpage><lpage>556</lpage><pub-id pub-id-type="doi">10.1016/j.jchromb.2008.09.020</pub-id><pub-id pub-id-type="pmid">18848512</pub-id></element-citation></ref><ref id="B24-pharmaceutics-13-02170"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Byon</surname><given-names>W.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>M.K.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>P.</given-names></name><name name-style="western"><surname>Tortorici</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Riley</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dai</surname><given-names>H.</given-names></name><name name-style="western"><surname>Dong</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ruiz-Garcia</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sweeney</surname><given-names>K.</given-names></name><name name-style="western"><surname>Cronenberger</surname><given-names>C.</given-names></name></person-group><article-title>Establishing best practices and guidance in population modeling: An experience with an internal population pharmacokinetic analysis guidance</article-title><source>CPT Pharmacomet. Syst. Pharmacol.</source><year>2013</year><volume>2</volume><fpage>e51</fpage><pub-id pub-id-type="doi">10.1038/psp.2013.26</pub-id><pub-id pub-id-type="pmcid">PMC6483270</pub-id><pub-id pub-id-type="pmid">23836283</pub-id></element-citation></ref><ref id="B25-pharmaceutics-13-02170"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lips</surname><given-names>M.</given-names></name><name name-style="western"><surname>Siller</surname><given-names>M.</given-names></name><name name-style="western"><surname>Strojil</surname><given-names>J.</given-names></name><name name-style="western"><surname>Urbanek</surname><given-names>K.</given-names></name><name name-style="western"><surname>Balik</surname><given-names>M.</given-names></name><name name-style="western"><surname>Suchankova</surname><given-names>H.</given-names></name></person-group><article-title>Pharmacokinetics of imipenem in critically ill patients during empirical treatment of nosocomial pneumonia: A comparison of 0.5-h and 3-h infusions</article-title><source>Int. J. Antimicrob. Agents</source><year>2014</year><volume>44</volume><fpage>358</fpage><lpage>362</lpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2014.05.011</pub-id><pub-id pub-id-type="pmid">25216543</pub-id></element-citation></ref><ref id="B26-pharmaceutics-13-02170"><label>26.</label><element-citation publication-type="webpage"><person-group person-group-type="author"><collab>Merck Sharp &amp; Dohme Corp</collab></person-group><article-title>Prescribing Information Primaxin (Imipenem and Cilastatin) for Injection, for Intravenous Use. USA, NJ, Whitehouse Station</article-title><year>2018</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.merck.com/product/usa/pi_circulars/p/primaxin/primaxin_iv_pi.pdf" ext-link-type="uri">https://www.merck.com/product/usa/pi_circulars/p/primaxin/primaxin_iv_pi.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2021-11-08">(accessed on 8 November 2021)</date-in-citation></element-citation></ref><ref id="B27-pharmaceutics-13-02170"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Keizer</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Karlsson</surname><given-names>M.O.</given-names></name><name name-style="western"><surname>Hooker</surname><given-names>A.</given-names></name></person-group><article-title>Modeling and Simulation Workbench for NONMEM: Tutorial on Pirana, PsN, and Xpose</article-title><source>CPT Pharmacomet. Syst. Pharmacol.</source><year>2013</year><volume>2</volume><fpage>e50</fpage><pub-id pub-id-type="doi">10.1038/psp.2013.24</pub-id><pub-id pub-id-type="pmid">23836189</pub-id><pub-id pub-id-type="pmcid">PMC3697037</pub-id></element-citation></ref><ref id="B28-pharmaceutics-13-02170"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Neely</surname><given-names>M.N.</given-names></name><name name-style="western"><surname>van Guilder</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Yamada</surname><given-names>W.M.</given-names></name><name name-style="western"><surname>Schumitzky</surname><given-names>A.</given-names></name><name name-style="western"><surname>Jelliffe</surname><given-names>R.W.</given-names></name></person-group><article-title>Accurate detection of outliers and subpopulations with Pmetrics, a nonparametric and parametric pharmacometric modeling and simulation package for R</article-title><source>Ther. Drug Monit.</source><year>2012</year><volume>34</volume><fpage>467</fpage><lpage>476</lpage><pub-id pub-id-type="doi">10.1097/FTD.0b013e31825c4ba6</pub-id><pub-id pub-id-type="pmid">22722776</pub-id><pub-id pub-id-type="pmcid">PMC3394880</pub-id></element-citation></ref><ref id="B29-pharmaceutics-13-02170"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baptista</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Neves</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rodrigues</surname><given-names>L.</given-names></name><name name-style="western"><surname>Teixeira</surname><given-names>L.</given-names></name><name name-style="western"><surname>Pinho</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pimentel</surname><given-names>J.</given-names></name></person-group><article-title>Accuracy of the estimation of glomerular filtration rate within a population of critically ill patients</article-title><source>J. Nephrol.</source><year>2014</year><volume>27</volume><fpage>403</fpage><lpage>410</lpage><pub-id pub-id-type="doi">10.1007/s40620-013-0036-x</pub-id><pub-id pub-id-type="pmid">24446348</pub-id></element-citation></ref><ref id="B30-pharmaceutics-13-02170"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hobbs</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Shea</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Daley</surname><given-names>M.J.</given-names></name></person-group><article-title>Implications of Augmented Renal Clearance on Drug Dosing in Critically Ill Patients: A Focus on Antibiotics</article-title><source>Pharmacotherapy</source><year>2015</year><volume>35</volume><fpage>1063</fpage><lpage>1075</lpage><pub-id pub-id-type="doi">10.1002/phar.1653</pub-id><pub-id pub-id-type="pmid">26598098</pub-id></element-citation></ref><ref id="B31-pharmaceutics-13-02170"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Belzberg</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Cornwell</surname><given-names>E.E.</given-names><suffix>3rd</suffix></name><name name-style="western"><surname>Murray</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Sava</surname><given-names>J.</given-names></name><name name-style="western"><surname>Salim</surname><given-names>A.</given-names></name><name name-style="western"><surname>Velmahos</surname><given-names>G.C.</given-names></name><name name-style="western"><surname>Gill</surname><given-names>M.A.</given-names></name></person-group><article-title>Imipenem levels are not predictable in the critically ill patient</article-title><source>J. Trauma</source><year>2004</year><volume>56</volume><fpage>111</fpage><lpage>117</lpage><pub-id pub-id-type="doi">10.1097/01.TA.0000056164.26493.28</pub-id><pub-id pub-id-type="pmid">14749576</pub-id></element-citation></ref><ref id="B32-pharmaceutics-13-02170"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roberts</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Lipman</surname><given-names>J.</given-names></name></person-group><article-title>Pharmacokinetic issues for antibiotics in the critically ill patient</article-title><source>Crit. Care Med.</source><year>2009</year><volume>37</volume><fpage>840</fpage><lpage>851</lpage><comment>quiz 859</comment><pub-id pub-id-type="doi">10.1097/CCM.0b013e3181961bff</pub-id><pub-id pub-id-type="pmid">19237886</pub-id></element-citation></ref><ref id="B33-pharmaceutics-13-02170"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jaruratanasirikul</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sudsai</surname><given-names>T.</given-names></name></person-group><article-title>Comparison of the pharmacodynamics of imipenem in patients with ventilator-associated pneumonia following administration by 2 or 0.5 h infusion</article-title><source>J. Antimicrob. Chemother.</source><year>2009</year><volume>63</volume><fpage>560</fpage><lpage>563</lpage><pub-id pub-id-type="doi">10.1093/jac/dkn543</pub-id><pub-id pub-id-type="pmid">19153079</pub-id></element-citation></ref><ref id="B34-pharmaceutics-13-02170"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Novelli</surname><given-names>A.</given-names></name><name name-style="western"><surname>Adembri</surname><given-names>C.</given-names></name><name name-style="western"><surname>Livi</surname><given-names>P.</given-names></name><name name-style="western"><surname>Fallani</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mazzei</surname><given-names>T.</given-names></name><name name-style="western"><surname>De Gaudio</surname><given-names>A.R.</given-names></name></person-group><article-title>Pharmacokinetic evaluation of meropenem and imipenem in critically ill patients with sepsis</article-title><source>Clin. Pharmacokinet.</source><year>2005</year><volume>44</volume><fpage>539</fpage><lpage>549</lpage><pub-id pub-id-type="doi">10.2165/00003088-200544050-00007</pub-id><pub-id pub-id-type="pmid">15871639</pub-id></element-citation></ref><ref id="B35-pharmaceutics-13-02170"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abhilash</surname><given-names>B.</given-names></name><name name-style="western"><surname>Tripathi</surname><given-names>C.D.</given-names></name><name name-style="western"><surname>Gogia</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Meshram</surname><given-names>G.G.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>M.</given-names></name><name name-style="western"><surname>Suraj</surname><given-names>B.</given-names></name></person-group><article-title>Pharmacokinetic/pharmacodynamic profiling of imipenem in patients admitted to an intensive care unit in India: A nonrandomized, cross-sectional, analytical, open-labeled study</article-title><source>Indian J. Crit. Care Med.</source><year>2015</year><volume>19</volume><fpage>587</fpage><lpage>592</lpage><pub-id pub-id-type="doi">10.4103/0972-5229.167036</pub-id><pub-id pub-id-type="pmid">26628823</pub-id><pub-id pub-id-type="pmcid">PMC4637958</pub-id></element-citation></ref><ref id="B36-pharmaceutics-13-02170"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brendel</surname><given-names>K.</given-names></name><name name-style="western"><surname>Dartois</surname><given-names>C.</given-names></name><name name-style="western"><surname>Comets</surname><given-names>E.</given-names></name><name name-style="western"><surname>Lemenuel-Diot</surname><given-names>A.</given-names></name><name name-style="western"><surname>Laveille</surname><given-names>C.</given-names></name><name name-style="western"><surname>Tranchand</surname><given-names>B.</given-names></name><name name-style="western"><surname>Girard</surname><given-names>P.</given-names></name><name name-style="western"><surname>Laffont</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Mentre</surname><given-names>F.</given-names></name></person-group><article-title>Are population pharmacokinetic and/or pharmacodynamic models adequately evaluated? A survey of the literature from 2002 to 2004</article-title><source>Clin. Pharmacokinet.</source><year>2007</year><volume>46</volume><fpage>221</fpage><lpage>234</lpage><pub-id pub-id-type="doi">10.2165/00003088-200746030-00003</pub-id><pub-id pub-id-type="pmid">17328581</pub-id><pub-id pub-id-type="pmcid">PMC2907410</pub-id></element-citation></ref><ref id="B37-pharmaceutics-13-02170"><label>37.</label><element-citation publication-type="webpage"><article-title>European Committee on Antimicrobial Susceptibility Testing Breakpoint Tables for Interpretation of MICs and Zone Diameters, Version 11.0</article-title><year>2021</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="www.eucast.org" ext-link-type="uri">www.eucast.org</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2021-11-08">(accessed on 8 November 2021)</date-in-citation></element-citation></ref><ref id="B38-pharmaceutics-13-02170"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Launay-Iliadis</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Bruno</surname><given-names>R.</given-names></name><name name-style="western"><surname>Cosson</surname><given-names>V.</given-names></name><name name-style="western"><surname>Vergniol</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Oulid-Aissa</surname><given-names>D.</given-names></name><name name-style="western"><surname>Marty</surname><given-names>M.</given-names></name><name name-style="western"><surname>Clavel</surname><given-names>M.</given-names></name><name name-style="western"><surname>Aapro</surname><given-names>M.</given-names></name><name name-style="western"><surname>Le Bail</surname><given-names>N.</given-names></name><name name-style="western"><surname>Iliadis</surname><given-names>A.</given-names></name></person-group><article-title>Population pharmacokinetics of docetaxel during phase I studies using nonlinear mixed-effect modeling and nonparametric maximum-likelihood estimation</article-title><source>Cancer Chemother. Pharmacol.</source><year>1995</year><volume>37</volume><fpage>47</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1007/BF00685628</pub-id><pub-id pub-id-type="pmid">7497596</pub-id></element-citation></ref><ref id="B39-pharmaceutics-13-02170"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vermes</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mathot</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>van der Sijs</surname><given-names>I.H.</given-names></name><name name-style="western"><surname>Dankert</surname><given-names>J.</given-names></name><name name-style="western"><surname>Guchelaar</surname><given-names>H.J.</given-names></name></person-group><article-title>Population pharmacokinetics of flucytosine: Comparison and validation of three models using STS, NPEM, and NONMEM</article-title><source>Ther. Drug Monit.</source><year>2000</year><volume>22</volume><fpage>676</fpage><lpage>687</lpage><pub-id pub-id-type="doi">10.1097/00007691-200012000-00006</pub-id><pub-id pub-id-type="pmid">11128235</pub-id></element-citation></ref><ref id="B40-pharmaceutics-13-02170"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Patoux</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bleyzac</surname><given-names>N.</given-names></name><name name-style="western"><surname>Boddy</surname><given-names>A.V.</given-names></name><name name-style="western"><surname>Doz</surname><given-names>F.</given-names></name><name name-style="western"><surname>Rubie</surname><given-names>H.</given-names></name><name name-style="western"><surname>Bastian</surname><given-names>G.</given-names></name><name name-style="western"><surname>Maire</surname><given-names>P.</given-names></name><name name-style="western"><surname>Canal</surname><given-names>P.</given-names></name><name name-style="western"><surname>Chatelut</surname><given-names>E.</given-names></name></person-group><article-title>Comparison of nonlinear mixed-effect and non-parametric expectation maximisation modelling for Bayesian estimation of carboplatin clearance in children</article-title><source>Eur. J. Clin. Pharmacol.</source><year>2001</year><volume>57</volume><fpage>297</fpage><lpage>303</lpage><pub-id pub-id-type="doi">10.1007/s002280100306</pub-id><pub-id pub-id-type="pmid">11549207</pub-id></element-citation></ref><ref id="B41-pharmaceutics-13-02170"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Hoog</surname><given-names>M.</given-names></name><name name-style="western"><surname>Schoemaker</surname><given-names>R.C.</given-names></name><name name-style="western"><surname>van den Anker</surname><given-names>J.N.</given-names></name><name name-style="western"><surname>Vinks</surname><given-names>A.A.</given-names></name></person-group><article-title>NONMEM and NPEM2 population modeling: A comparison using tobramycin data in neonates</article-title><source>Ther. Drug Monit.</source><year>2002</year><volume>24</volume><fpage>359</fpage><lpage>365</lpage><pub-id pub-id-type="doi">10.1097/00007691-200206000-00006</pub-id><pub-id pub-id-type="pmid">12021626</pub-id></element-citation></ref><ref id="B42-pharmaceutics-13-02170"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Woillard</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Debord</surname><given-names>J.</given-names></name><name name-style="western"><surname>Benz-de-Bretagne</surname><given-names>I.</given-names></name><name name-style="western"><surname>Saint-Marcoux</surname><given-names>F.</given-names></name><name name-style="western"><surname>Turlure</surname><given-names>P.</given-names></name><name name-style="western"><surname>Girault</surname><given-names>S.</given-names></name><name name-style="western"><surname>Abraham</surname><given-names>J.</given-names></name><name name-style="western"><surname>Choquet</surname><given-names>S.</given-names></name><name name-style="western"><surname>Marquet</surname><given-names>P.</given-names></name><name name-style="western"><surname>Barin-Le Guellec</surname><given-names>C.</given-names></name></person-group><article-title>A Time-Dependent Model Describes Methotrexate Elimination and Supports Dynamic Modification of MRP2/ABCC2 Activity</article-title><source>Ther. Drug Monit.</source><year>2017</year><volume>39</volume><fpage>145</fpage><lpage>156</lpage><pub-id pub-id-type="doi">10.1097/FTD.0000000000000381</pub-id><pub-id pub-id-type="pmid">28196047</pub-id></element-citation></ref><ref id="B43-pharmaceutics-13-02170"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Woillard</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Lebreton</surname><given-names>V.</given-names></name><name name-style="western"><surname>Neely</surname><given-names>M.</given-names></name><name name-style="western"><surname>Turlure</surname><given-names>P.</given-names></name><name name-style="western"><surname>Girault</surname><given-names>S.</given-names></name><name name-style="western"><surname>Debord</surname><given-names>J.</given-names></name><name name-style="western"><surname>Marquet</surname><given-names>P.</given-names></name><name name-style="western"><surname>Saint-Marcoux</surname><given-names>F.</given-names></name></person-group><article-title>Pharmacokinetic tools for the dose adjustment of ciclosporin in haematopoietic stem cell transplant patients</article-title><source>Br. J. Clin. Pharmacol.</source><year>2014</year><volume>78</volume><fpage>836</fpage><lpage>846</lpage><pub-id pub-id-type="doi">10.1111/bcp.12394</pub-id><pub-id pub-id-type="pmid">24698009</pub-id><pub-id pub-id-type="pmcid">PMC4239977</pub-id></element-citation></ref><ref id="B44-pharmaceutics-13-02170"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Premaud</surname><given-names>A.</given-names></name><name name-style="western"><surname>Weber</surname><given-names>L.T.</given-names></name><name name-style="western"><surname>Tonshoff</surname><given-names>B.</given-names></name><name name-style="western"><surname>Armstrong</surname><given-names>V.W.</given-names></name><name name-style="western"><surname>Oellerich</surname><given-names>M.</given-names></name><name name-style="western"><surname>Urien</surname><given-names>S.</given-names></name><name name-style="western"><surname>Marquet</surname><given-names>P.</given-names></name><name name-style="western"><surname>Rousseau</surname><given-names>A.</given-names></name></person-group><article-title>Population pharmacokinetics of mycophenolic acid in pediatric renal transplant patients using parametric and nonparametric approaches</article-title><source>Pharmacol. Res.</source><year>2011</year><volume>63</volume><fpage>216</fpage><lpage>224</lpage><pub-id pub-id-type="doi">10.1016/j.phrs.2010.10.017</pub-id><pub-id pub-id-type="pmid">21056671</pub-id></element-citation></ref><ref id="B45-pharmaceutics-13-02170"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bustad</surname><given-names>A.</given-names></name><name name-style="western"><surname>Terziivanov</surname><given-names>D.</given-names></name><name name-style="western"><surname>Leary</surname><given-names>R.</given-names></name><name name-style="western"><surname>Port</surname><given-names>R.</given-names></name><name name-style="western"><surname>Schumitzky</surname><given-names>A.</given-names></name><name name-style="western"><surname>Jelliffe</surname><given-names>R.</given-names></name></person-group><article-title>Parametric and nonparametric population methods: Their comparative performance in analysing a clinical dataset and two Monte Carlo simulation studies</article-title><source>Clin. Pharmacokinet.</source><year>2006</year><volume>45</volume><fpage>365</fpage><lpage>383</lpage><pub-id pub-id-type="doi">10.2165/00003088-200645040-00003</pub-id><pub-id pub-id-type="pmid">16584284</pub-id></element-citation></ref><ref id="B46-pharmaceutics-13-02170"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baverel</surname><given-names>P.G.</given-names></name><name name-style="western"><surname>Savic</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Wilkins</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Karlsson</surname><given-names>M.O.</given-names></name></person-group><article-title>Evaluation of the nonparametric estimation method in NONMEM VI: Application to real data</article-title><source>J. Pharmacokinet. Pharmacodyn.</source><year>2009</year><volume>36</volume><fpage>297</fpage><lpage>315</lpage><pub-id pub-id-type="doi">10.1007/s10928-009-9122-z</pub-id><pub-id pub-id-type="pmid">19572188</pub-id></element-citation></ref><ref id="B47-pharmaceutics-13-02170"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carlsson</surname><given-names>K.C.</given-names></name><name name-style="western"><surname>van de Schootbrugge</surname><given-names>M.</given-names></name><name name-style="western"><surname>Eriksen</surname><given-names>H.O.</given-names></name><name name-style="western"><surname>Moberg</surname><given-names>E.R.</given-names></name><name name-style="western"><surname>Karlsson</surname><given-names>M.O.</given-names></name><name name-style="western"><surname>Hoem</surname><given-names>N.O.</given-names></name></person-group><article-title>A population pharmacokinetic model of gabapentin developed in nonparametric adaptive grid and nonlinear mixed effects modeling</article-title><source>Ther. Drug Monit.</source><year>2009</year><volume>31</volume><fpage>86</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1097/FTD.0b013e318194767d</pub-id><pub-id pub-id-type="pmid">19077930</pub-id></element-citation></ref><ref id="B48-pharmaceutics-13-02170"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bulitta</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Landersdorfer</surname><given-names>C.B.</given-names></name><name name-style="western"><surname>Kinzig</surname><given-names>M.</given-names></name><name name-style="western"><surname>Holzgrabe</surname><given-names>U.</given-names></name><name name-style="western"><surname>Sorgel</surname><given-names>F.</given-names></name></person-group><article-title>New semiphysiological absorption model to assess the pharmacodynamic profile of cefuroxime axetil using nonparametric and parametric population pharmacokinetics</article-title><source>Antimicrob. Agents Chemother.</source><year>2009</year><volume>53</volume><fpage>3462</fpage><lpage>3471</lpage><pub-id pub-id-type="doi">10.1128/AAC.00054-09</pub-id><pub-id pub-id-type="pmid">19528278</pub-id><pub-id pub-id-type="pmcid">PMC2715586</pub-id></element-citation></ref><ref id="B49-pharmaceutics-13-02170"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bulitta</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Landersdorfer</surname><given-names>C.B.</given-names></name><name name-style="western"><surname>Huttner</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Drusano</surname><given-names>G.L.</given-names></name><name name-style="western"><surname>Kinzig</surname><given-names>M.</given-names></name><name name-style="western"><surname>Holzgrabe</surname><given-names>U.</given-names></name><name name-style="western"><surname>Stephan</surname><given-names>U.</given-names></name><name name-style="western"><surname>Sorgel</surname><given-names>F.</given-names></name></person-group><article-title>Population pharmacokinetic comparison and pharmacodynamic breakpoints of ceftazidime in cystic fibrosis patients and healthy volunteers</article-title><source>Antimicrob. Agents Chemother.</source><year>2010</year><volume>54</volume><fpage>1275</fpage><lpage>1282</lpage><pub-id pub-id-type="doi">10.1128/AAC.00936-09</pub-id><pub-id pub-id-type="pmid">20065059</pub-id><pub-id pub-id-type="pmcid">PMC2826012</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="pharmaceutics-13-02170-f001" orientation="portrait"><label>Figure 1</label><caption><p>Individual (I [IPRED], II, and III) and population (I (PRED), IV, and V) concentrations, predicted using the parametric model (<bold>a</bold>) and the nonparametric model (<bold>b</bold>), plotted against the observed concentrations of the external dataset. The two dose groups, 500 mg and 1000 mg, are differentiated in graphs II and IV and two eGFR groups (measured by the CKD-EPI unadjusted for BSA) in graphs III and V. The log-transformed concentrations of the parametric model (<bold>a</bold>) are back transformed for an easier comparison with the untransformed concentrations in the figures of the nonparametric model (<bold>b</bold>).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pharmaceutics-13-02170-g001a.jpg"/><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pharmaceutics-13-02170-g001b.jpg"/><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pharmaceutics-13-02170-g001c.jpg"/></fig><fig position="float" id="pharmaceutics-13-02170-f002" orientation="portrait"><label>Figure 2</label><caption><p>Visual Predictive Checks (VPCs) of both models using the external validation database. Circles: observed concentrations. Upper, middle, and lower lines: 95th, 50th, and 5th percentile of observations. Shaded areas: 95%CI of the corresponding percentiles of predictions. I: both dose regimens, II: 500 mg, III: 1000 mg, IV: eGFR 20&#8211;59 mL/min, V: eGFR 79&#8211;178 mL/min. The log-transformed concentrations of the parametric model (<bold>a</bold>) are back transformed for an easier comparison with the untransformed concentrations in the figures of the nonparametric model (<bold>b</bold>).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pharmaceutics-13-02170-g002a.jpg"/><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pharmaceutics-13-02170-g002b.jpg"/><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pharmaceutics-13-02170-g002c.jpg"/></fig><table-wrap position="float" id="pharmaceutics-13-02170-t001" orientation="portrait"><object-id pub-id-type="pii">pharmaceutics-13-02170-t001_Table 1</object-id><label>Table 1</label><caption><p>Demographic and clinical characteristics of the population (<italic toggle="yes">n</italic> = 26) used to build the popPK models and of the validation population (<italic toggle="yes">n</italic> = 19). APACHE, Acute Physiology and Chronic Health Evaluation; eGFR, estimated Glomerular Filtration Range; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; BMI, Body Mass Index; BSA, Body Surface Area.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Parameter</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Modeling<break/>Population</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Validation Population</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">Male, <italic toggle="yes">n</italic> (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">18 (69)</td><td align="center" valign="middle" rowspan="1" colspan="1">14 (74)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">APACHE II score, median (range)</td><td align="center" valign="middle" rowspan="1" colspan="1">22 (7&#8211;35)</td><td align="center" valign="middle" rowspan="1" colspan="1">26 (13&#8211;42)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Age (years), median (range) </td><td align="center" valign="middle" rowspan="1" colspan="1">51 (25&#8211;59)</td><td align="center" valign="middle" rowspan="1" colspan="1">64 (26&#8211;90)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Creatinine at inclusion (&#956;mol/L), median (range)</td><td align="center" valign="middle" rowspan="1" colspan="1">59 (28&#8211;108)</td><td align="center" valign="middle" rowspan="1" colspan="1">98 (44&#8211;235)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">eGFR CKD-EPI at inclusion (ml/min/1.73 m<sup>2</sup>), median (range)</td><td align="center" valign="middle" rowspan="1" colspan="1">116 (50&#8211;143)</td><td align="center" valign="middle" rowspan="1" colspan="1">73 (20&#8211;145)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">eGFR absolute CKD-EPI at inclusion, unadjusted for BSA (ml/min), median (range)</td><td align="center" valign="middle" rowspan="1" colspan="1">119 (51&#8211;172)</td><td align="center" valign="middle" rowspan="1" colspan="1">79 (19&#8211;178)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Height (cm), median (range)</td><td align="center" valign="middle" rowspan="1" colspan="1">175 (155&#8211;190)</td><td align="center" valign="middle" rowspan="1" colspan="1">170 (150&#8211;190)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Total bodyweight (kg), median (range)</td><td align="center" valign="middle" rowspan="1" colspan="1">75 (50&#8211;107)</td><td align="center" valign="middle" rowspan="1" colspan="1">78 (45&#8211;110)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>), median (range)</td><td align="center" valign="middle" rowspan="1" colspan="1">25 (18&#8211;35)</td><td align="center" valign="middle" rowspan="1" colspan="1">28 (18&#8211;34)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">BSA (m<sup>2</sup>), median (range)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.89 (1.51&#8211;2.23)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.92 (1.40&#8211;2.29)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Presumed infection, <italic toggle="yes">n</italic> (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"> Respiratory tract infection</td><td align="center" valign="middle" rowspan="1" colspan="1">16 (62)</td><td align="center" valign="middle" rowspan="1" colspan="1">19 (100)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"> Intra-abdominal infection</td><td align="center" valign="middle" rowspan="1" colspan="1">4 (15)</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"> Bloodstream infection</td><td align="center" valign="middle" rowspan="1" colspan="1">3 (12)</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"> Surgical site infection</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (4)</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"> Meningitis</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (4)</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"> Gynecological infection</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 (4)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr></tbody></table></table-wrap><table-wrap position="float" id="pharmaceutics-13-02170-t002" orientation="portrait"><object-id pub-id-type="pii">pharmaceutics-13-02170-t002_Table 2</object-id><label>Table 2</label><caption><p>Prediction errors of the parametric and nonparametric popPK models using the external validation database (111 concentrations). The prediction errors were also calculated after 1000 simulations (111.000 concentrations) of both models. In the last 4 columns, a selection of the simulations (trough levels only) per eGFR group are shown. PE = prediction error (mg/L) = individual predicted concentration&#8212;observed concentration. RPE = relative prediction error (%) = prediction error/observed concentration.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">KERRYPNX</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">External Database</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Simulations</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Simulations (Selection)</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Simulations (Selection)</th></tr><tr><th colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">111 Concentrations</th><th colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">1000 &#215; 111 Concentrations</th><th colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">1000 &#215; 17 trough eGFR19-59</th><th colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">1000 &#215; 18 trough eGFR79-178</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Parametric</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>PE (mg/L)</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>RPE (%)</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>PE (mg/L)</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>RPE (%)</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>PE (mg/L)</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>RPE (%)</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>PE (mg/L)</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>RPE (%)</bold>
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">97.5%</td><td align="center" valign="middle" rowspan="1" colspan="1">3.83</td><td align="center" valign="middle" rowspan="1" colspan="1">105</td><td align="center" valign="middle" rowspan="1" colspan="1">8.97</td><td align="center" valign="middle" rowspan="1" colspan="1">252</td><td align="center" valign="middle" rowspan="1" colspan="1">9.74</td><td align="center" valign="middle" rowspan="1" colspan="1">360</td><td align="center" valign="middle" rowspan="1" colspan="1">2.03</td><td align="center" valign="middle" rowspan="1" colspan="1">225</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">75%</td><td align="center" valign="middle" rowspan="1" colspan="1">0.61</td><td align="center" valign="middle" rowspan="1" colspan="1">19</td><td align="center" valign="middle" rowspan="1" colspan="1">1.97</td><td align="center" valign="middle" rowspan="1" colspan="1">56</td><td align="center" valign="middle" rowspan="1" colspan="1">3.92</td><td align="center" valign="middle" rowspan="1" colspan="1">167</td><td align="center" valign="middle" rowspan="1" colspan="1">0.38</td><td align="center" valign="middle" rowspan="1" colspan="1">31</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">50%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.02</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.04</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.13</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">83</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.50</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;24</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">25%</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;1.52</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;20</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;2.20</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;31</td><td align="center" valign="middle" rowspan="1" colspan="1">0.72</td><td align="center" valign="middle" rowspan="1" colspan="1">23</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;1.64</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;53</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.5%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;30.55</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;52</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;28.63</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;74</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;3.16</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;41</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;3.15</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;82</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>Nonparametric</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>PE (mg/L)</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>RPE (%)</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>PE (mg/L)</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>RPE (%)</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>PE (mg/L)</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>RPE (%)</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>PE (mg/L)</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>RPE (%)</bold>
</td></tr><tr><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">97.5%</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">3.89</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">54</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">30.68</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">594</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">28.96</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">996</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">7.08</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">564</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">75%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.51</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.22</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">83</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.66</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">221</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.80</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">58</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">50%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.43</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;9</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.02</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.24</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">88</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.33</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;19</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">25%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;1.74</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;29</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;2.47</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;39</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.32</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;1.56</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;56</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.5%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;25.99</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;58</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;24.77</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;79</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;4.15</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;63</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;3.36</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;91</td></tr></tbody></table></table-wrap><table-wrap position="float" id="pharmaceutics-13-02170-t003" orientation="portrait"><object-id pub-id-type="pii">pharmaceutics-13-02170-t003_Table 3</object-id><label>Table 3</label><caption><p>The highest MIC for which a probability of target attainment (PTA) of 97.5% is reached at targets of 50% and 100% <italic toggle="yes">f</italic>T &gt; MIC by several imipenem dosing regimens and eGFR values (measured by the CKD-EPI equation unadjusted for BSA) of 150, 120, and 90 mL/min. The PTAs were calculated by Monte Carlo simulations (<italic toggle="yes">n</italic> = 5000) using parametric and nonparametric popPK models.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">eGFR (ml/min)</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Dose Regimen</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Target <italic toggle="yes">f</italic>T <sub>&gt; MIC</sub></th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Highest MIC (mg/L)<break/>with PTA &gt; 97.5%</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Parametric</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nonparametric</th></tr></thead><tbody><tr><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">150</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">500 mg q6h</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.125</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.06</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1000 mg q8h</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.125</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.03</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1000 mg q6h</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.25</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.125</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">500 mg q6h</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">50%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.25</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1000 mg q8h</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">50%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.5</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1000 mg q6h</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">50%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td></tr><tr><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">120</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">500 mg q6h</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.125</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.125</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1000 mg q8h</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.25</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.06</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1000 mg q6h</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.25</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.25</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">500 mg q6h</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">50%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.5</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1000 mg q8h</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">50%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.5</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1000 mg q6h</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">50%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td></tr><tr><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">90</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">500 mg q6h</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.25</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.25</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1000 mg q8h</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.25</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.25</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1000 mg q6h</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.5</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">500 mg q6h</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">50%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.5</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1000 mg q8h</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">50%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1000 mg q6h</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">50%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td></tr></tbody></table></table-wrap></floats-group></article></pmc-articleset>